The relationship between the metabolic syndrome and the risk of benign prostatic hyperplasia: A hospital-based study from a health screening population

Korean Journal of Urology

Volumn 48, Issue 10, 2007, Pages 1016-1021

  Kwon, Nam Sung ^a   Jo, Moon Ki ^a   Park, Kwanjin ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Benign prostatic hyperplasia; Metabolic syndrome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; HIGH RISK POPULATION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLIC SYNDROME X; PREVALENCE; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 35848939392     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.10.1016     Document Type: Review

References (23)

1. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237-46
2. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203
3. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168:599-604
4. Hammarsten J, Hogstedt B. Hyporinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39: 151-8
5. Kim JH, Shim BS, Kim JS, Hong YS. Voiding dysfunction of men is associated with metabolic syndrome. Korean J Urol 2006;47:257-62
6. Sohn JC, Chang HS, Kim CI. The correlation between metabolic syndrome and the prostate volume. Korean J Urol 2007; 48:603-7
7. Park JS, Park JK. The meaning of metabolic syndrome X in patients suffering with benign prostatic hyperplasia. Korean J Urol 2007;48:696-700
8. Export panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) export panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97
9. WHO Regional Office for the Western Pacific/International Association for the Study of Obesity/International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney, Health Communications Australia, 2000.
10. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36
11. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62
12. Hammarsten J, Hogstedt B. Calculated fast-growing benign prostatic hyporplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002;36:330-8
13. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006;68:1198-205
14. Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, Talamini R, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes 2005;29: 798-803
15. Burke JP, Rhodes T, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, et al. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol 2006;164:41-6
16. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44
17. Seitter WR, Barrett-Connor E. Cigarette smoking, obesity, and benign prostatic hyportrophy: a prospoctive population-based study. Am J Epidemiol 1992;135:500-3
18. Gann PH, Hennekens CH, Longcopo C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40-9
19. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyporplasia with age. J Urol 1984; 132:474-9
20. Park HK, Lee KS, KCHAR, Hart BK, Jeong SJ, Hong SK, et al. The relationship between metabolic syndrome and voiding dysfunction in aged men of local community. Korean J Urol 2006;47(Suppl 2):141, abstract P-29
21. Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostatic biology. J Androl 1996;17:2-4
22. Lyre YL, Hwang SW, Shim HJ, Oh EH, Chang YS, Cho BL. Prevalence and risk factors of the metabolic syndrome as defined by NCEP-ATP III. J Korean Acad Fam Med 2003;24:135-43
23. Kim BS. Prevalence of metabolic syndrome for Koreans. Korean J Health Promot Dis 2002;2:17-25